Related Experiment Video

Updated: Aug 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Pharmacoeconomic considerations with statin therapy

Katie M Speidel1, Daniel E Hilleman

  • 1The Cardiac Center of Creighton University, 3006 Webster Street, Omaha, NE 68131-2044, USA. katie.speidel@cardiac.creighton.edu

Expert Opinion on Pharmacotherapy
|June 30, 2006
PubMed

Insights

Statins effectively reduce cardiovascular events and mortality, proving cost-effective. Current research emphasizes optimizing statin therapy with high-intensity dosing for greater low-density lipoprotein cholesterol reduction and patient benefit.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacoeconomics
  • Clinical Pharmacology

Background:

  • Statins are proven to reduce morbidity and mortality in diverse patient populations.
  • Previous economic evaluations confirmed the cost-effectiveness of statins based on mortality trials.
  • Placebo-controlled trials offer limited guidance for current statin selection decisions.

Purpose of the Study:

  • To review the evolving landscape of statin therapy optimization.
  • To highlight the need for economic analyses of comparative statin studies.
  • To inform drug therapy selection and formulary decisions.

Main Methods:

  • Review of recent clinical trials comparing different statin intensities.
  • Analysis of findings regarding low-density lipoprotein cholesterol reduction efficacy.
  • Identification of the gap in published economic evaluations for comparative studies.

Main Results:

  • More intensive statin therapy, with higher doses, yields greater low-density lipoprotein cholesterol reduction and clinical benefit.
  • Statins demonstrating superior efficacy in lowering low-density lipoprotein cholesterol are preferred.
  • Economic analyses of these comparative studies are currently lacking.

Conclusions:

  • Optimizing statin therapy requires considering high-intensity regimens for enhanced patient outcomes.
  • Comparative efficacy in low-density lipoprotein cholesterol reduction is a key factor in selecting statins.
  • Urgent need for pharmacoeconomic studies to guide evidence-based statin selection and formulary placement.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...